HRP20090577T1 - Upotreba crth2 antagonista spojeva u industriji - Google Patents

Upotreba crth2 antagonista spojeva u industriji Download PDF

Info

Publication number
HRP20090577T1
HRP20090577T1 HR20090577T HRP20090577T HRP20090577T1 HR P20090577 T1 HRP20090577 T1 HR P20090577T1 HR 20090577 T HR20090577 T HR 20090577T HR P20090577 T HRP20090577 T HR P20090577T HR P20090577 T1 HRP20090577 T1 HR P20090577T1
Authority
HR
Croatia
Prior art keywords
methyl
fluoro
indol
acetic acid
alkyl
Prior art date
Application number
HR20090577T
Other languages
English (en)
Croatian (hr)
Inventor
Middlemiss David
Richard Ashton Mark
Andrew Boyd Edward
Arthur Brookfield Frederick
Roy Pettipher Eric
Whittaker Mark
Palmer Christopher
Hunter Mick
Original Assignee
Oxagen Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Limited filed Critical Oxagen Limited
Publication of HRP20090577T8 publication Critical patent/HRP20090577T8/xx
Publication of HRP20090577T1 publication Critical patent/HRP20090577T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20090577T 2003-10-23 2004-10-19 Upotreba crth2 antagonista spojeva u industriji HRP20090577T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324763.2A GB0324763D0 (en) 2003-10-23 2003-10-23 Use of compounds in therapy
PCT/GB2004/004417 WO2005044260A1 (en) 2003-10-23 2004-10-19 Use of crth2 antagonist compounds in therapy

Publications (2)

Publication Number Publication Date
HRP20090577T8 HRP20090577T8 (en) 2009-12-31
HRP20090577T1 true HRP20090577T1 (hr) 2009-12-31

Family

ID=29595698

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090577T HRP20090577T1 (hr) 2003-10-23 2004-10-19 Upotreba crth2 antagonista spojeva u industriji

Country Status (25)

Country Link
US (5) US7582672B2 (OSRAM)
EP (2) EP1682121B1 (OSRAM)
JP (1) JP4313819B2 (OSRAM)
KR (1) KR20060096145A (OSRAM)
CN (1) CN101141956B (OSRAM)
AT (1) ATE439129T1 (OSRAM)
AU (1) AU2004287245B2 (OSRAM)
BR (1) BRPI0415374B8 (OSRAM)
CA (1) CA2543199C (OSRAM)
CY (1) CY1109980T1 (OSRAM)
DE (1) DE602004022579D1 (OSRAM)
DK (1) DK1682121T3 (OSRAM)
ES (1) ES2330113T3 (OSRAM)
GB (1) GB0324763D0 (OSRAM)
HR (1) HRP20090577T1 (OSRAM)
IL (1) IL175085A0 (OSRAM)
NO (1) NO335228B1 (OSRAM)
NZ (1) NZ547319A (OSRAM)
PL (1) PL1682121T3 (OSRAM)
PT (1) PT1682121E (OSRAM)
RU (1) RU2412934C2 (OSRAM)
SI (1) SI1682121T1 (OSRAM)
UA (1) UA86602C2 (OSRAM)
WO (1) WO2005044260A1 (OSRAM)
ZA (1) ZA200603235B (OSRAM)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
CN101084190B (zh) 2004-12-27 2011-01-26 埃科特莱茵药品有限公司 作为crth2受体拮抗剂的2,3,4,9-四氢-1h-咔唑衍生物
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
GB0512944D0 (en) * 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
EP1911759A4 (en) 2005-07-22 2010-07-21 Shionogi & Co AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
EP2397476A3 (en) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Indole derivative having PGD2 receptor antagonist activity
GB0518783D0 (en) * 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
US8053449B2 (en) * 2005-10-05 2011-11-08 Cell Viable Corporation Method for inhibiting AGE complex formation
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
ES2380683T3 (es) * 2005-12-15 2012-05-17 Astrazeneca Ab Difenil-éteres, -amidas, -sulfuros y - metanos sustituidos para el tratamiento de la enfermedad respiratoria
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
PL2037967T3 (pl) 2006-06-16 2017-07-31 The Trustees Of The University Of Pennsylvania Antagoniści receptora prostaglandyny D2 w leczeniu łysienia androgenowego
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
CA2658986C (en) 2006-08-07 2014-11-25 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
US20100010034A1 (en) * 2006-12-21 2010-01-14 George Hynd Crth2 antagonists
EA200970875A1 (ru) * 2007-03-21 2010-04-30 Арджента Орал Терапьютикс Лимитед Производные индолизинуксусной кислоты в качестве антагонистов crth2
EP2139330B1 (en) * 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Methods involving aldose reductase inhibitors
MX2009010376A (es) * 2007-03-29 2010-01-20 Argenta Oral Therapeutics Ltd Derivados de quinolina como ligandos del receptor crth2.
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
WO2009061730A2 (en) 2007-11-05 2009-05-14 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
GB0722203D0 (en) * 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
EP2327693B9 (en) * 2007-12-14 2012-10-24 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
NZ587251A (en) 2008-01-18 2011-12-22 Oxagen Ltd Indole derivatives having CRTH2 antagonist activity
WO2009093026A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
EP2240444A1 (en) * 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
EP2257524B1 (en) 2008-02-01 2016-01-06 Brickell Biotech, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
JP2011518130A (ja) 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
WO2010008864A2 (en) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
WO2010003120A2 (en) 2008-07-03 2010-01-07 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US20120004233A1 (en) * 2009-01-26 2012-01-05 Amira Pharmaceuticals, Inc Tricyclic compounds as antagonists of prostaglandin d2 receptors
WO2010089391A1 (en) * 2009-02-09 2010-08-12 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
KR20120046762A (ko) * 2009-07-31 2012-05-10 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 피부 제형
EP2461809A4 (en) * 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
CA2768587A1 (en) 2009-08-05 2011-02-10 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
CA2782085A1 (en) 2010-01-06 2011-07-14 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
US9397745B2 (en) 2010-05-18 2016-07-19 Qualcomm Incorporated Hybrid satellite and mesh network system for aircraft and ship internet service
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
KR20130133219A (ko) * 2010-12-23 2013-12-06 머크 샤프 앤드 돔 코포레이션 Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用
CN103086943B (zh) * 2011-11-04 2015-04-15 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类衍生物
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
JP6186933B2 (ja) * 2013-06-21 2017-08-30 富士通株式会社 接合シート及びその製造方法、並びに放熱機構及びその製造方法
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
TWI649321B (zh) 2014-03-17 2019-02-01 瑞士商愛杜西亞製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
MX2018000947A (es) 2015-07-23 2018-06-07 Merck Sharp & Dohme Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2.
HK1256553A1 (zh) 2015-07-30 2019-09-27 The Trustees Of The University Of Pennsylvania 用於检测pgd2对毛发生长抑制的易感性的人dp-2基因的单核苷酸多态性等位基因
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
WO2018014867A1 (zh) 2016-07-21 2018-01-25 正大天晴药业集团股份有限公司 作为crth2抑制剂的三并环类化合物
EP3489233B1 (en) * 2016-07-21 2022-01-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indole derivative used as crth2 inhibitor
CN108101829B (zh) * 2017-11-19 2020-05-12 华南理工大学 一种吲哚化合物、其制备方法及应用
EP3741754A4 (en) 2018-01-19 2021-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. INDOLE DERIVATIVE CRYSTALLINE FORM AND PROCESS OF PREPARATION AND USE
EP3902794A1 (en) 2018-12-27 2021-11-03 Chiesi Farmaceutici S.p.A. Process for preparing spherical agglomerates of timapiprant
WO2023030487A1 (zh) * 2021-09-03 2023-03-09 深圳零一生命科技有限责任公司 吲哚类化合物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4324418Y1 (OSRAM) 1965-04-06 1968-10-15
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
US3577142A (en) * 1969-02-28 1971-05-04 Westinghouse Learning Corp Code translation system
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB1407658A (en) 1973-03-06 1975-09-24 Ici Ltd Process for the manufacture of indole derivatives
GB1460348A (en) 1974-02-04 1977-01-06 Ici Ltd Quinazoline derivativesa
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
GB9122590D0 (en) * 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
JP3228381B2 (ja) * 1993-10-29 2001-11-12 ソニー株式会社 Ａｖセレクタ
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
NZ310559A (en) * 1995-06-21 1999-05-28 Shionogi & Co Bicyclic sulphonamide and carboxamide derivatives and medicaments
DE69734141T2 (de) 1996-06-05 2006-07-13 Bml Inc. PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER
TR200002446T2 (tr) 1998-02-25 2000-12-21 Genetics Institute, Inc. Fosfolipaz enzimlerinin inhibitörleri
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU774929B2 (en) * 1998-03-31 2004-07-15 Institutes For Pharmaceutical Discovery, Llc, The Substituted indolealkanoic acids
GB9825524D0 (en) * 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
CA2383135C (en) 1999-08-23 2010-11-30 Hiroyuki Hirai Method of identifying properties of substance with respect to human prostaglandin d2 receptors
WO2001051489A2 (en) * 2000-01-14 2001-07-19 The Institutes For Pharmaceutical Discovery, Llc Methods for lowering uric acid levels
EP1166011A1 (en) 2000-01-14 2002-01-02 Koninklijke Philips Electronics N.V. Display device
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
JP2001247570A (ja) 2000-03-08 2001-09-11 Japan Tobacco Inc インドール酢酸化合物及びその製造方法
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
JPWO2003097042A1 (ja) 2002-05-16 2005-09-15 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗剤
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
US7364647B2 (en) 2002-07-17 2008-04-29 Eksigent Technologies Llc Laminated flow device
CA2509170A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
JP4324418B2 (ja) 2003-08-05 2009-09-02 株式会社日立国際電気 基板処理装置および半導体デバイスの製造方法
EP1675826A1 (en) * 2003-10-14 2006-07-05 Oxagen Limited Compounds having crth2 antagonist activity
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
WO2006110051A1 (en) * 2005-04-12 2006-10-19 Auckland Uniservices Ltd Pressure assisted thermal sterilisation or pasteurisation method and apparatus
PL65781Y1 (pl) 2005-08-16 2012-02-29 Katarzyna Kawczyńska Wkładka kosmetyczna
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
NZ587251A (en) 2008-01-18 2011-12-22 Oxagen Ltd Indole derivatives having CRTH2 antagonist activity
EP2240444A1 (en) * 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
WO2009093026A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity

Also Published As

Publication number Publication date
US7582672B2 (en) 2009-09-01
ATE439129T1 (de) 2009-08-15
US8314257B2 (en) 2012-11-20
CN101141956A (zh) 2008-03-12
SI1682121T1 (sl) 2010-01-29
BRPI0415374A (pt) 2006-12-12
HK1093435A1 (en) 2007-03-02
HRP20090577T8 (en) 2009-12-31
US20090018338A1 (en) 2009-01-15
ES2330113T3 (es) 2009-12-04
EP2060258A1 (en) 2009-05-20
JP2007509114A (ja) 2007-04-12
JP4313819B2 (ja) 2009-08-12
AU2004287245A1 (en) 2005-05-19
US8163931B2 (en) 2012-04-24
US8198314B2 (en) 2012-06-12
US20090023788A1 (en) 2009-01-22
DK1682121T3 (da) 2009-10-26
BRPI0415374B8 (pt) 2021-05-25
US20090018139A1 (en) 2009-01-15
EP1682121B1 (en) 2009-08-12
EP1682121A1 (en) 2006-07-26
NZ547319A (en) 2009-03-31
CA2543199C (en) 2014-09-23
CN101141956B (zh) 2011-04-20
CY1109980T1 (el) 2014-09-10
NO335228B1 (no) 2014-10-27
IL175085A0 (en) 2008-04-13
PT1682121E (pt) 2009-11-03
RU2006109769A (ru) 2007-11-27
UA86602C2 (ru) 2009-05-12
CA2543199A1 (en) 2005-05-19
US20090018138A1 (en) 2009-01-15
NO20061456L (no) 2006-07-20
ZA200603235B (en) 2009-03-25
BRPI0415374B1 (pt) 2018-10-09
KR20060096145A (ko) 2006-09-07
WO2005044260A1 (en) 2005-05-19
RU2412934C2 (ru) 2011-02-27
PL1682121T3 (pl) 2010-01-29
US8163936B2 (en) 2012-04-24
GB0324763D0 (en) 2003-11-26
AU2004287245B2 (en) 2009-03-26
DE602004022579D1 (de) 2009-09-24
US20050119268A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
HRP20090577T1 (hr) Upotreba crth2 antagonista spojeva u industriji
JP2007509114A5 (OSRAM)
RU2006109108A (ru) Соединения, обладающие активностью антагонистов crth2 рецепторов
US8044088B2 (en) 1-acetic acid-indole derivatives with PGD2 antagonist activity
AU2009204700B2 (en) Compounds having CRTH2 antagonist activity
RU2170730C2 (ru) Хинолиновые карбоксамиды и фармацевтическая композиция на их основе
ES2393630T3 (es) Derivados de N-(AMINO-HETEROARIL)-1H-INDOL-2-CARBOXAMIDAS, su preparación y su aplicación en terapéutica
RU2008137633A (ru) Соли, проявляющие антогонизм в отношении рецептора crth-2
JP2011509990A (ja) Ｃｒｔｈ２アンタゴニスト活性を有する化合物
ES2985738T3 (es) Compuestos de 2-oxindol
MX2007010588A (es) Acido (5-fluoro-2-metil-3-quinolin-2-ilmetil-indol-1-il) acetico microcristalino.
ES2342318T3 (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1.
JP2959128B2 (ja) インドール誘導体
RS50853B (sr) Derivati n-(1h-indolil)-1h-indol-2-karboksamida, njihova priprema i njihova primena u terapiji
WO2008017710A1 (en) 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
TW205040B (OSRAM)
HK1093435B (en) Use of crth2 antagonist compounds in therapy
HK1109628B (en) 1-acetic acid-indole derivatives with pgd2 antagonist activity